PL1909600T3 - Kompozycja spowalniająca metabolizm alkoholu i ograniczająca ryzyko chorób wywołanych alkoholem - Google Patents
Kompozycja spowalniająca metabolizm alkoholu i ograniczająca ryzyko chorób wywołanych alkoholemInfo
- Publication number
- PL1909600T3 PL1909600T3 PL06762860T PL06762860T PL1909600T3 PL 1909600 T3 PL1909600 T3 PL 1909600T3 PL 06762860 T PL06762860 T PL 06762860T PL 06762860 T PL06762860 T PL 06762860T PL 1909600 T3 PL1909600 T3 PL 1909600T3
- Authority
- PL
- Poland
- Prior art keywords
- composition
- alcohol
- risk
- reducing
- food
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract 3
- 208000017167 Alcohol-Induced disease Diseases 0.000 title 1
- 230000004060 metabolic process Effects 0.000 title 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 4
- 230000000378 dietary effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000022099 Alzheimer disease 2 Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05016563 | 2005-07-29 | ||
| EP05016565 | 2005-07-29 | ||
| EP05016567 | 2005-07-29 | ||
| EP05016568 | 2005-07-29 | ||
| EP05016566 | 2005-07-29 | ||
| EP05016564 | 2005-07-29 | ||
| PCT/EP2005/009147 WO2007016949A1 (en) | 2005-07-29 | 2005-08-24 | Composition for reducing the risc of alcohol induced neuropathy |
| PCT/EP2005/009151 WO2007016953A1 (en) | 2005-07-29 | 2005-08-24 | Composition for reducing alcohol induced liver cancer risk |
| PCT/EP2005/009153 WO2007016955A1 (en) | 2005-07-29 | 2005-08-24 | Alcohol metabolism moderating composition |
| PCT/EP2005/009152 WO2007016954A1 (en) | 2005-07-29 | 2005-08-24 | Composition for reducing drug or alcohol induced breast cancer risk |
| PCT/EP2005/009148 WO2007016950A1 (en) | 2005-07-29 | 2005-08-24 | Composition for reducing the risk of alcohol induced neurodegenerative disease |
| PCT/EP2005/009150 WO2007016952A1 (en) | 2005-07-29 | 2005-08-24 | Composition for reducing the risk of alcohol induced esophagenal and oropharyngolaryngeal cancer |
| PCT/EP2005/009149 WO2007016951A1 (en) | 2005-07-29 | 2005-08-24 | Composition for reducing the risc of alcohol induced pancreatic cancer |
| PCT/EP2006/007466 WO2007017139A1 (en) | 2005-07-29 | 2006-07-27 | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
| EP06762860A EP1909600B1 (en) | 2005-07-29 | 2006-07-27 | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1909600T3 true PL1909600T3 (pl) | 2012-09-28 |
Family
ID=39573667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06762860T PL1909600T3 (pl) | 2005-07-29 | 2006-07-27 | Kompozycja spowalniająca metabolizm alkoholu i ograniczająca ryzyko chorób wywołanych alkoholem |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8580750B2 (pl) |
| EP (1) | EP1909600B1 (pl) |
| JP (2) | JP5371428B2 (pl) |
| KR (2) | KR101487848B1 (pl) |
| CN (1) | CN101232822B (pl) |
| AT (1) | ATE554663T1 (pl) |
| AU (1) | AU2006278823B2 (pl) |
| CA (1) | CA2611389C (pl) |
| CY (1) | CY1113015T1 (pl) |
| DK (1) | DK1909600T3 (pl) |
| EA (1) | EA012753B1 (pl) |
| ES (1) | ES2386460T3 (pl) |
| HK (1) | HK1117709A1 (pl) |
| HR (1) | HRP20120489T1 (pl) |
| PL (1) | PL1909600T3 (pl) |
| PT (1) | PT1909600E (pl) |
| SI (1) | SI1909600T1 (pl) |
| UA (1) | UA94713C2 (pl) |
| WO (1) | WO2007017139A1 (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8633192B2 (en) | 2006-12-15 | 2014-01-21 | Tima Foundation | Compositions and uses thereof |
| KR101487852B1 (ko) * | 2006-12-15 | 2015-01-29 | 티마 파운데이션 | 신규조성물 및 그 용도 |
| EP2057905A1 (en) * | 2007-11-12 | 2009-05-13 | TIMA Foundation | Composition for moderating Triglyceride and Cholesterol Levels |
| NZ587134A (en) * | 2008-01-24 | 2012-04-27 | Raptor Therapeutics Inc | Protopanaxadiol-type ginsenoside compositions and uses thereof |
| WO2010033045A1 (en) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions and methods for prevention or treatment of beta amyloid deposition |
| KR20110115862A (ko) * | 2010-04-16 | 2011-10-24 | 씨제이제일제당 (주) | 숙취 해소 및 예방용 조성물과 이를 이용한 음주전 후 숙취해소용 음료 |
| WO2012095509A1 (en) * | 2011-01-14 | 2012-07-19 | Tima Foundation | Composition for accelerating alcohol metabolism and for reducing the risk of alcohol induced diseases |
| DE102011001768A1 (de) | 2011-04-04 | 2012-10-04 | Gunnar Frank | Präparat oder Nahrungsergänzungsmittel |
| JP6092844B2 (ja) * | 2011-04-04 | 2017-03-08 | バーグ エルエルシー | 中枢神経系腫瘍の治療方法 |
| US20130116215A1 (en) * | 2011-10-28 | 2013-05-09 | Mireia Coma | Combination therapies for treating neurological disorders |
| EP2594141A1 (en) * | 2011-11-15 | 2013-05-22 | TIMA Foundation | Composition for protection against cell-damaging effects |
| JP5777821B2 (ja) * | 2011-11-15 | 2015-09-09 | ティーマ ファウンデーション | 細胞傷害作用からの防御のための組成物 |
| JP6437823B2 (ja) * | 2011-11-22 | 2018-12-12 | ザ・ジョンズ・ホプキンス・ユニバーシティ | アルコール毒性低減のための方法および組成物 |
| WO2014011676A1 (en) | 2012-07-09 | 2014-01-16 | Tolleth Robert J | Prevention of alcohol reaction with dietary supplements |
| US9161957B2 (en) | 2012-08-03 | 2015-10-20 | Life Well Lived, Llc | Compositions and methods for reducing blood alcohol content |
| CA2929338A1 (en) * | 2013-11-06 | 2015-05-14 | Salim JARROUJ | Composition and method for increasing the rate of alcohol metabolism and preventing hangover symptoms |
| JP6681338B2 (ja) | 2014-11-07 | 2020-04-15 | 株式会社ニチレイバイオサイエンス | アルコール代謝促進剤 |
| WO2017212113A1 (en) | 2016-06-06 | 2017-12-14 | Catapult Cat Oy | Combination of l-cysteine, ascorbic acid and vitamin b3 for treating hangover |
| JP6935994B2 (ja) | 2016-08-19 | 2021-09-15 | 株式会社明治 | ケトン体生成促進用組成物 |
| AU2017363147B2 (en) * | 2016-11-17 | 2023-09-14 | Biojiva Llc | Isotopically modified components and therapeutic uses thereof |
| KR102150040B1 (ko) * | 2018-10-16 | 2020-08-31 | 한국과학기술원 | 4-메틸피라졸을 포함하는 간암 예방 또는 치료용 조성물 |
| CN109125310A (zh) * | 2018-11-06 | 2019-01-04 | 河北工业大学 | 琥珀酸在抑制Kv10.1离子通道活性中的应用和药物 |
| CN110339233B (zh) * | 2019-04-01 | 2021-10-19 | 山东济世药业有限公司 | 一种用于防治酒精性肝损伤的组合物及其制备方法和用途 |
| CN114081891A (zh) * | 2020-08-24 | 2022-02-25 | 山西好医生药业有限公司 | 一种五维葡萄糖的制备工艺及其应用 |
| JP2022132160A (ja) * | 2021-02-26 | 2022-09-07 | 国立大学法人北海道大学 | がんの治療又は予防剤、及びがんの治療又は予防のためのｒｆ経路阻害剤とｍｅｋ阻害剤との組み合わせ |
| CN114891808B (zh) * | 2022-06-21 | 2023-10-27 | 珠海丽凡达生物技术有限公司 | 编码ALDH2多肽的mRNA分子、应用及mRNA药物 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US19427A (en) * | 1858-02-23 | Improvement in steam-plows | ||
| US124198A (en) * | 1872-03-05 | Improvement in devices for cutting off tubes | ||
| US1082196A (en) * | 1913-04-16 | 1913-12-23 | Alois Helfenstein | Electric furnace. |
| JPS5535049A (en) | 1978-09-04 | 1980-03-11 | Otsuka Pharmaceut Factory Inc | Amino acid transfusion for cancerous patient |
| US5409905A (en) * | 1981-01-05 | 1995-04-25 | Eby, Iii; George A. | Cure for commond cold |
| GB2118437B (en) | 1982-03-01 | 1984-12-12 | Efamol Ltd | Composition for treating alcoholism |
| US4496548A (en) | 1983-02-04 | 1985-01-29 | Moldowan Mervin J | Composition and method for reducing hangover |
| EP0185117A1 (de) | 1984-12-21 | 1986-06-25 | IPEX Getränke-Herstellungs- und Vertriebsgesellschaft mbH | Getränk |
| GB8521275D0 (en) * | 1985-08-27 | 1985-10-02 | Blass D H | Therapeutic composition |
| PH22818A (en) | 1986-02-18 | 1989-01-19 | Takeda Chemical Industries Ltd | Composition and method for reducing acetaldehyde toxicity |
| JP2560808B2 (ja) * | 1988-11-02 | 1996-12-04 | 味の素株式会社 | アミノ酸及びペッパー抽出物含有酒類 |
| US6294520B1 (en) | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
| JP3051413B2 (ja) * | 1989-07-20 | 2000-06-12 | アルバート・ティー・ナイトー | 血液脳関門を通過する物質 |
| CN1058914A (zh) * | 1991-03-16 | 1992-02-26 | 肖宏生 | 酒液多功能口服液 |
| JPH04342528A (ja) | 1991-05-17 | 1992-11-30 | Toyama Chem Co Ltd | アルコール代謝およびアセトアルデヒド代謝促進剤 |
| EP0617958A4 (de) * | 1992-07-06 | 1995-09-06 | Irina Alexeevna Komissarova | pharmazeutische Zusammensetzung zur Behandlung von Alkoholismus, zur Stimulierungvon Katabolismus und Magensekretion und zumSchutze gegen Strahlenbeschädigung und Cholera. |
| RU2012350C1 (ru) * | 1993-05-17 | 1994-05-15 | Александр Михайлович Шепеленко | Средство для снятия алкогольного опьянения |
| JPH0733653A (ja) * | 1993-06-25 | 1995-02-03 | Suntory Ltd | アセトアルデヒド毒性の抑制剤 |
| US5475031A (en) | 1993-09-03 | 1995-12-12 | Livingston; William H. | Discovery of a valuable property for succinic acid and other intermediary metabolites |
| GB9526741D0 (en) | 1995-12-30 | 1996-02-28 | Sobering Thoughts Ltd | Product for combatting dehydration |
| IL117773A (en) | 1996-04-02 | 2000-10-31 | Pharmos Ltd | Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability |
| FR2748935A1 (fr) * | 1996-05-23 | 1997-11-28 | Clergeaud Jean | Solution buvable favorisant la baisse du taux d'alcoolemie |
| CN1170578A (zh) * | 1996-07-17 | 1998-01-21 | 中国人民解放军第四军医大学 | 地龙胶囊 |
| IT1291113B1 (it) | 1997-03-20 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Composizione nutritiva terapeutica per soggetti affetti da diabete mellito |
| US6537969B1 (en) * | 1997-10-24 | 2003-03-25 | John P. Blass | Nutritional supplement for cerebral metabolic insufficiencies |
| US6667063B2 (en) | 1998-06-10 | 2003-12-23 | Albert Crum | Nutritional or therapeutic supplement and method |
| AT411958B8 (de) | 1998-11-19 | 2004-09-27 | Jhs Privatstiftung | Erfrischungsgetränk zur steigerung der alkohol-abbau-kapazität |
| AU2001243369A1 (en) | 2000-03-14 | 2001-09-24 | Massachusetts Institute Of Technology | Composition and method to treat weight gain and obesity attributable to psychotropic drugs |
| US6299896B1 (en) * | 2000-04-13 | 2001-10-09 | Cooper Concepts, Inc. | Multi-vitamin and mineral supplement |
| US6420342B1 (en) * | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
| US20020006910A1 (en) | 2000-05-18 | 2002-01-17 | Dmitri Miasnikov | Means for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome and a method for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome by using this means |
| DE60028376T2 (de) | 2000-10-09 | 2007-06-06 | Rath, Matthias, Dr. | Therapeutische Kombination des Ascorbats mit Lysin und Arginin für Verhinderung und Behandlung des Krebses |
| US6630158B2 (en) | 2000-10-31 | 2003-10-07 | Stiefel Laboratories, Inc. | Dietary supplement composition and method for improving and maintaining healthy skin |
| US6964969B2 (en) | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
| AUPR626101A0 (en) * | 2001-07-10 | 2001-08-02 | Mcgregor, Neil | A composition and uses therefor |
| TWI239245B (en) * | 2001-07-13 | 2005-09-11 | Takara Bio Inc | Medical composition for oral administration or intravenous administration for a disease requiring enhancement of nerve growth factor production for treatment or prevention |
| KR20030032484A (ko) * | 2001-10-18 | 2003-04-26 | 롯데제과주식회사 | 발암 억제효능을 갖는 데오브로민 |
| JP4119640B2 (ja) * | 2001-10-26 | 2008-07-16 | 株式会社大塚製薬工場 | 飲酒時の不快症状軽減剤 |
| US20040067986A1 (en) * | 2002-10-04 | 2004-04-08 | Nathan Sassover | Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer |
| US6821536B2 (en) * | 2002-11-22 | 2004-11-23 | Quercegen Holdings Llc | Antioxidative compositions |
| CN100361599C (zh) * | 2002-10-23 | 2008-01-16 | 克尔塞根控股有限公司 | 抗氧化组合物 |
| KR20040045146A (ko) * | 2002-11-22 | 2004-06-01 | (주) 내츄로에이스 | 숙취 제거 및 피로회복을 위한 생약 조성물 및 이를이용한 건강보조식품 |
| KR20040094173A (ko) * | 2003-05-02 | 2004-11-09 | 장경케어그룹 주식회사 | 백년초-건조분말 및 이를 포함하는 숙취제거용 조성물 |
| DE10326822A1 (de) | 2003-06-11 | 2005-01-05 | Herzpharma Vita-Check Diagnosegeräte GmbH | Mittel zur Nahrungsergänzung, dieses Mittel enthaltende pharmazeutische Präparate und Verwendungen des Mittels |
| US6936283B2 (en) | 2003-07-25 | 2005-08-30 | Langeland Bjoern T. | Composition for stimulation of specific metallo-enzymes |
| RU2240789C1 (ru) * | 2003-12-24 | 2004-11-27 | Закрытое акционерное общество "НПО ПЦ БИОФИЗИКА" | Средство, обладающее гепатопротекторными свойствами, для снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома |
| EA011721B1 (ru) * | 2004-02-17 | 2009-04-28 | Маркус Граф В. Матушка-Грейффенклау | Композиция для сдерживания деградации алкоголя в организме человека |
| US20050238638A1 (en) * | 2004-04-21 | 2005-10-27 | Jonathan Gutwein | Dietary Supplement that Serves as a Carbohydrate Blocker and Hangover Remedy |
| US20050238710A1 (en) * | 2004-04-23 | 2005-10-27 | Philip Connolly | Vitamin replacement as a hangover ameliorative |
| US20050271754A1 (en) * | 2004-06-07 | 2005-12-08 | Cochrane Patrick W | Composition for prevention or treatment of an alcohol hangover |
| US8633192B2 (en) * | 2006-12-15 | 2014-01-21 | Tima Foundation | Compositions and uses thereof |
-
2006
- 2006-07-27 US US11/997,127 patent/US8580750B2/en active Active
- 2006-07-27 CA CA2611389A patent/CA2611389C/en active Active
- 2006-07-27 UA UAA200800602A patent/UA94713C2/uk unknown
- 2006-07-27 DK DK06762860.2T patent/DK1909600T3/da active
- 2006-07-27 CN CN2006800278400A patent/CN101232822B/zh active Active
- 2006-07-27 ES ES06762860T patent/ES2386460T3/es active Active
- 2006-07-27 EA EA200800427A patent/EA012753B1/ru not_active IP Right Cessation
- 2006-07-27 WO PCT/EP2006/007466 patent/WO2007017139A1/en active Application Filing
- 2006-07-27 PT PT06762860T patent/PT1909600E/pt unknown
- 2006-07-27 JP JP2008523251A patent/JP5371428B2/ja active Active
- 2006-07-27 EP EP06762860A patent/EP1909600B1/en active Active
- 2006-07-27 AU AU2006278823A patent/AU2006278823B2/en not_active Ceased
- 2006-07-27 SI SI200631337T patent/SI1909600T1/sl unknown
- 2006-07-27 KR KR20137031344A patent/KR101487848B1/ko active IP Right Grant
- 2006-07-27 AT AT06762860T patent/ATE554663T1/de active
- 2006-07-27 PL PL06762860T patent/PL1909600T3/pl unknown
- 2006-07-27 KR KR1020077028054A patent/KR101562271B1/ko active IP Right Grant
-
2008
- 2008-09-24 HK HK08110628.1A patent/HK1117709A1/xx not_active IP Right Cessation
-
2012
- 2012-06-12 CY CY20121100530T patent/CY1113015T1/el unknown
- 2012-06-12 HR HRP20120489TT patent/HRP20120489T1/hr unknown
-
2013
- 2013-04-25 JP JP2013091972A patent/JP5785581B2/ja active Active
- 2013-10-21 US US14/058,388 patent/US9402849B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20140105877A1 (en) | 2014-04-17 |
| EP1909600A1 (en) | 2008-04-16 |
| JP5785581B2 (ja) | 2015-09-30 |
| CA2611389A1 (en) | 2007-02-15 |
| WO2007017139A1 (en) | 2007-02-15 |
| AU2006278823B2 (en) | 2011-05-12 |
| JP5371428B2 (ja) | 2013-12-18 |
| US20090054351A1 (en) | 2009-02-26 |
| CN101232822B (zh) | 2012-11-14 |
| CA2611389C (en) | 2015-02-17 |
| KR101562271B1 (ko) | 2015-10-21 |
| US9402849B2 (en) | 2016-08-02 |
| CN101232822A (zh) | 2008-07-30 |
| ES2386460T3 (es) | 2012-08-21 |
| DK1909600T3 (da) | 2012-07-30 |
| JP2013189437A (ja) | 2013-09-26 |
| EA200800427A1 (ru) | 2008-06-30 |
| JP2009516639A (ja) | 2009-04-23 |
| US8580750B2 (en) | 2013-11-12 |
| HK1117709A1 (en) | 2009-01-23 |
| KR20130137719A (ko) | 2013-12-17 |
| KR101487848B1 (ko) | 2015-02-03 |
| UA94713C2 (uk) | 2011-06-10 |
| EP1909600B1 (en) | 2012-04-25 |
| SI1909600T1 (sl) | 2012-07-31 |
| KR20080033899A (ko) | 2008-04-17 |
| PT1909600E (pt) | 2012-07-24 |
| CY1113015T1 (el) | 2016-04-13 |
| EA012753B1 (ru) | 2009-12-30 |
| AU2006278823A1 (en) | 2007-02-15 |
| ATE554663T1 (de) | 2012-05-15 |
| HRP20120489T1 (hr) | 2012-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1117709A1 (en) | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases | |
| HK1157337A1 (pl) | ||
| MX2009002921A (es) | Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico. | |
| MX2007003506A (es) | Terapia de combinacion de cancer que comprende azd2171 e imatinib. | |
| MX2009006704A (es) | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. | |
| TW200724537A (en) | Pyrimidine derivatives for treatment of hyperproliferative disorders | |
| HK1078771A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer | |
| MY151449A (en) | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 | |
| MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
| WO2008087367A3 (fr) | Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazodyl)-phenyl-propan-1-one substitues, preparations et utilisations | |
| UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
| EP1971338B8 (en) | Combination of zd6474 and pemetrexed | |
| EP2061456A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING P450 CYTOCHROME | |
| TW200621732A (en) | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | |
| IN2012DN05186A (pl) | ||
| PL1965801T3 (pl) | Połączenie AZD2171 i premetreksedu | |
| EP2131849A4 (en) | COMPOSITIONS AND METHODS OF DISTRIBUTING AGENTS AGAINST CANCER | |
| WO2008135661A3 (fr) | Utilisation de la citrulline pour pour le traitement de pathologies liees a une augmentation de la carbonylation des protéines | |
| WO2007003933A3 (en) | Combination therapy of cancer with azd2171 and gemcitabine | |
| HK1096022A1 (en) | Combination therapy with azd-2171[73] astrazeneca ab s-151 85 södertälje sweden | |
| WO2004004660A3 (en) | Compositions and methods for the treatment of parkinson’s disease and tardive dyskinesias | |
| WO2005083425A3 (en) | Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 13 (map3k13) | |
| HU0500590D0 (en) | Process for preparation of pharmaceutical compositions for the treatment of psoriasis and suggestion for the therapy |